A Long Term Follow-up Study of TScan TCR-T Products
Cancer-Related Syndrome
Leukemia
Myelodysplastic Syndromes (MDS)
18 - 110 Years, Male and Female
TSCAN-004 (primary)
NCI-2025-06747
Summary
The purpose of this Long-Term Follow-Up (LTFU) study is to monitor participants who have
previously received TSC-100 or TSC-101 TCR-T therapies in the TSCAN-001 study.
Participants will be monitored for 15 years from the date of TCR-T cell therapy
administration to assess long-term safety and efficacy.
Objectives
Participants will enroll in this LTFU study after completing the TSCAN-001 interventional
trial. No additional study drug will be administered; however, participants may receive
other cancer treatments as needed while being monitored for long-term safety.
Enrollment will occur after completion of the TSCAN-001 study, and participants will be
monitored for safety and efficacy over a 15 year period.
Eligibility
- Participants who received a TCR-T cellular therapy in a clinical study sponsored by TScan Therapeutics.
- Signed informed consent.
Treatment Sites in Georgia
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-851-8523
Doctors:
Melhem Solh MD
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.